Filtern
Erscheinungsjahr
Dokumenttyp
- Vortrag (49)
Referierte Publikation
- nein (49)
Schlagworte
- Immunoassay (19)
- Biosensoren (10)
- Antibody (6)
- Biosensor (5)
- ELISA (4)
- SARS-CoV-2 (4)
- Schnelltest (4)
- Antikörper (3)
- Elektrochemisch (2)
- FPIA (2)
Organisationseinheit der BAM
Eingeladener Vortrag
- nein (49) (entfernen)
The assessment of water quality demands for multi-target compatible analytical methods. On the one hand, the influence of sewage on natural surface waters must be routinely monitored. On the other hand, estimation of removal efficiencies of pollutants, such as drug residues, is in the focus of industrial and public wastewater treatment. Immunoassays, such as ELISA, are often applied in this area, however, it is only possible to measure a single analyte in one measurement.
In contrast, array technology is capable for measuring multiple substances in parallel. Here we present a four-plex bead-based flow cytometric assay for measuring three drugs (carbamazepine, an antiepileptic drug, diclofenac, an antiphlogistic and caffeine, a psychoactive substance) and the bile acid isolithocholic acid, which is proposed to be used as a fecal marker.
In this suspension array core-shell particles, consisting of a polystyrene core and a silica shell, are used. They can be easily encoded with a fluorophore which is introduced to the core while the shell is functionalized with amino groups to which the analytes or their derivates are bound via NHS chemistry. They are the competitor binding sites for the antibodies.
For the determination of the pollutants, the beads are incubated with a mixture of the analyte-specific antibodies. The molecules on the surface of the beads and the free analyte in solution compete for the binding sites of the antibodies. Bead-bound antibodies can then be visualized via dye-labelled secondary antibodies. For read-out a flow cytometer is used to virtually separate the differently encoded beads. In order to obtain highly selective binding of the antibodies, we investigated different types of surface modifications to overcome unspecific binding, finding that a PEG-based surface is suitable to support our immunoassay format. The resulting multiplexing assay is appropriate to detect the marker substances in the low µg/L range.
The lab-on-valve (LOV) is a mesofluidic platform that has been recently exploited for
the automation and miniaturization of bioanalytical assays, resorting namely to
molecular recognition schemes based on immunosensing. Due to its high versatility
for reagent accommodation, it is possible to establish immunoassays under several
formats (eg. direct competitive ELISA, sandwich ELISA or even label-free immunoaffinity
chromatography). For instance, the LOV has been used as a manifold for
UV-vis micro-Bead Injection Spectroscopy (μ-BIS), a technique that involves the
quantification of the target analyte by direct measurement on the surface of a solid
phase capable of retaining the target analyte by molecular recognition.
The μ-BIS-LOV strategy affords several analytical advantages, namely short time-toresult
intervals (3 to 15 min), low sample volume (1-20 μL), automated solution handling
and washing steps, downscaling of reagents’ consumption, low-cost analysis
and little generation of waste. Additionally, the solid support is renewed before each
determination, minimizing surface fouling, cross-contamination issues and functional
group deactivation. No sample clean-up steps are required because interferences
are separated from the target analyte upon quantification mediated by a molecular
recognition element attached to the micro-bead column. The portability of the LOV
device makes it compatible with point-of-care testing.
To our knowledge, this technique has been mainly employed for the evaluation and
optimization of bioaffinity processes, but its potential for clinical and environmental
analysis remains underexploited. Hence, in this communication, different immunosensing
strategies using the LOV platform will be addressed, namely the determination
of autoimmune IgG in human serum, and the assessment of drug (carbamazepine)
levels in wastewater samples.